Lecigimon

Package leaflet: Information for the user

Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinal gel

levodopa/carbidopa monohydrate/entacapone
Please read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only. Do not give it to other people, even if they have the same symptoms as yours, because it could be harmful.
• If you experience any side effect, including those not listed in this leaflet, contact your doctor, pharmacist or nurse. See section 4.

Contents of this leaflet:

1. What Lecigimon is and what it is used for
2. What you need to know before using Lecigimon
3. How to use Lecigimon
4. Possible side effects
5. How to store Lecigimon
6. Contents of the pack and other information

1. What Lecigimon is and what it is used for

Lecigimon is used for the treatment of Parkinson's disease. It is used in advanced cases
when oral medications (medicines taken by mouth) are no longer producing a sufficient effect.
Lecigimon is a gel for continuous administration that is delivered via a pump and a
catheter directly into the small intestine. Lecigimon contains three active substances:

• levodopa
• carbidopa (in the form of carbidopa monohydrate)
• entacapone

How Lecigimon works
Dopamine levels in the brain of a person with Parkinson's disease are low. Levodopa is converted into dopamine in the brain, thereby reducing the symptoms of Parkinson's disease. Carbidopa and entacapone enhance the effect of levodopa on Parkinson's disease.

2. What you should know before using Lecigimon

Do not use Lecigimon if:

• You are allergic to levodopa, carbidopa, entacapone, or any of the other ingredients of this medicine (listed in section 6)
• You suffer from a type of eye disorder known as closed-angle glaucoma (a type of acute glaucoma)
• You suffer from severe heart failure
• You have a severely irregular heartbeat (arrhythmia)
• You have recently had a stroke
• You have severe liver disease
• You are taking medicines for depression called selective MAO-A inhibitors (such as moclobemide) or non-selective MAO inhibitors (such as phenelzine). Treatment with these medicines must be stopped at least two weeks before starting treatment with Lecigimon. See also section “Other medicines and Lecigimon”:
• You have a tumour of the adrenal gland causing overproduction of adrenaline and noradrenaline (pheochromocytoma)
• Your body produces too much cortisol (Cushing's syndrome)
• Your thyroid hormone levels are too high (hyperthyroidism)
• You have ever experienced Neuroleptic Malignant Syndrome (NMS) (a rare, serious reaction occurring during or after stopping treatment with certain medicines)
• You have ever experienced rhabdomyolysis (a rare, serious muscle condition affecting the kidneys)
• You have ever had skin cancer or have moles or unusual marks on your skin that have not been examined by a doctor

Warnings and precautions
Talk to your doctor before using Lecigimon if you suffer or have previously suffered from:

• Heart attack or any other cardiovascular disease, including angina and irregular heartbeat
• Asthma or other lung diseases
• Kidney or liver disease
• A hormonal disorder
• Stomach ulcer
• Seizures (convulsions)
• Severe psychiatric disorders, such as psychosis
• An eye condition called open-angle glaucoma
• Upper gastrointestinal surgery

If any of the following symptoms occur during treatment with Lecigimon, contact a doctor immediately:

• Neuroleptic Malignant Syndrome: A serious condition characterised by a combination of muscle rigidity, cramps, tremors, sweating, fever, rapid pulse, severe fluctuations in blood pressure, acting out, confusion, or loss of consciousness.
• Rhabdomyolysis: A serious condition associated with unexplained muscle pain, muscle cramps, or muscle weakness. Rhabdomyolysis may occur secondary to neuroleptic malignant syndrome. → For further information on neuroleptic malignant syndrome and rhabdomyolysis, see section 3 "If you stop or reduce the dose of Lecigimon" and section 4 "Possible side effects".
• Problems caused by the tube or surgery: Stomach pain, nausea, or vomiting. These may be due to serious complications from the tube or surgery, such as blockage, injury, or damage to the intestine.

If any of the following symptoms occur during treatment with Lecigimon, contact a doctor immediately:

• You feel depressed, express suicidal thoughts, or if you or others notice any changes in your mental state
• You notice the appearance of moles or unusual skin marks that have suddenly appeared or worsened
• You develop involuntary movements (dyskinesia). If you have not previously been treated with entacapone (one of the active substances in Lecigimon), these symptoms may be due to entacapone enhancing the effects of levodopa and carbidopa (other active substances in Lecigimon). Your doctor may need to reduce the dosage.
• You feel that the effect of treatment is worsening suddenly or gradually, for example, difficulty moving or slow movements (bradykinesia). This may be due to

the tube having dislodged from its position in the small intestine or being blocked. Or the
pump may not be functioning properly.

• You experience diarrhoea. Body weight monitoring may be necessary to prevent excessive weight loss, or treatment interruption may be required. Prolonged or persistent diarrhoea may indicate intestinal inflammation. In such cases, your doctor should reassess your treatment with Lecigimon.
• You experience progressive loss of appetite, a feeling of weakness, and weight loss over a relatively short period. A general medical check-up may be needed, including liver function tests.

If you are unable to manage the pump and tube, you must ask for help from someone assisting you
(e.g. a nurse, nursing assistant, or close relative) to avoid complications (problems).
Impulse control disorders: behavioural changes
Inform your doctor if you, your family members, or caregivers notice that you are developing an urge or desire to behave in unusual ways and are unable to resist the impulse, drive, or temptation to carry out certain activities that could harm yourself or others.
These behaviours are called "impulse control disorders" and may include gambling addiction, excessive spending or eating, abnormally increased sexual drive, or increased thoughts or urges related to sex. Your doctor may need to review or discontinue your treatment. For more information, see section 4 “Possible side effects”.
Dopamine dysregulation syndrome
Inform your doctor if you or your family/caregivers notice symptoms resembling addiction, such as a desire for increasingly higher doses of Lecigimon and other medicines used to treat Parkinson’s disease.
Regular monitoring
With long-term treatment with Lecigimon, your doctor may need to perform regular checks of liver and kidney function, blood counts, heart and blood vessels, and examine your skin for any changes.
Lecigimon and cancer
Lecigimon contains hydrazine, which forms when carbidopa (an active ingredient in Lecigimon) breaks down. Hydrazine could cause damage to your genes, potentially increasing the risk of developing cancer. However, it is not known whether the amount of hydrazine produced during the recommended dose of Lecigimon could cause harm or disease.
Surgery
Before undergoing any surgical procedure, including dental surgery, inform your doctor or dentist that you are using Lecigimon.
Urine tests
The active ingredients levodopa and carbidopa may cause misleading results in urine tests. Inform the healthcare professional if you are asked to provide a urine sample that you are using Lecigimon.
Children and adolescents
Lecigimon must not be given to children or adolescents under 18 years of age.
Other medicines and Lecigimon
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Do not use Lecigimon if you are taking:

• Medicines for depression called selective MAO-A inhibitors (such as moclobemide) or non-selective MAO inhibitors (such as phenelzine). Treatment with these medicines must be stopped at least two weeks before starting treatment with Lecigimon.

Lecigimon may enhance the effectiveness and side effects of other medicines, and other medicines may enhance the effectiveness and side effects of Lecigimon. Inform your doctor if you are taking:

• Medicines for depression called tricyclic antidepressants (such as clomipramine, amitriptyline, and nortriptyline). Other types of antidepressants may also interact with or be affected by Lecigimon.
• Medicines for Parkinson’s disease called selective MAO-B inhibitors (such as selegiline), amantadine, dopamine agonists (such as piribedil), and anticholinergics (such as biperiden).
• Medicines for urinary incontinence (such as oxybutynin), asthma, and chronic obstructive pulmonary disease (COPD) (such as ipratropium and tiotropium). These medicines are known as anticholinergics.
• Certain medicines for asthma and allergies (such as salbutamol and terbutaline) and adrenaline. These medicines are known as sympathomimetics.
• Medicines to lower blood pressure (so-called antihypertensives). Concomitant use of these medicines with Lecigimon may cause a drop in blood pressure when rising from a sitting or lying position. A dose adjustment of the antihypertensive may be necessary.
• Warfarin (a medicine to prevent blood clots). If you are being treated with Lecigimon or start, stop, or change your Lecigimon treatment, the effect of warfarin must be monitored.

Some medicines may reduce the effectiveness of Lecigimon. Inform your doctor if you are taking:

• Any oral iron-containing products (tablets, capsules, solutions). Iron may impair absorption of levodopa from the gastrointestinal tract (and vice versa). Lecigimon and oral iron preparations should therefore be taken at least 2–3 hours apart. If the pump is not used during the night, iron supplements may be taken before bedtime.
• Medicines for psychosis (such as phenothiazines, butyrophenones (e.g. haloperidol), and risperidone).
• Medicines for nausea (such as metoclopramide).
• Medicines for epilepsy (such as clonazepam and phenytoin).
• Medicines for anxiety and sleeping problems, known as benzodiazepines (such as diazepam, oxazepam, and nitrazepam).
• Medicines for tuberculosis (isoniazid).
• Medicines for gastrointestinal cramps (papaverine).

Lecigimon with food and drink
Lecigimon is poorly absorbed if taken immediately after high-protein meals (such as meat, fish, dairy products, seeds, and nuts). Consult your doctor if you are on a high-protein diet.
Pregnancy, breastfeeding, and fertility
If you are pregnant, think you might be pregnant, planning to become pregnant, or breastfeeding, ask your doctor or pharmacist for advice before taking this medicine.
Use of Lecigimon during pregnancy or in women of childbearing potential who are not using contraception is not recommended unless your doctor considers that the benefits to the mother outweigh the possible risks to the foetus.
Breastfeeding must be avoided during treatment with Lecigimon.
Driving and using machines
Lecigimon may have a major influence on the ability to drive and use machines. Do not drive or operate machinery until you know how Lecigimon affects you.

• Lecigimon may cause drowsiness or may occasionally cause you to fall asleep suddenly (sleep attacks).
• Lecigimon may cause a drop in blood pressure, for example, when rising from a sitting or lying position, and cause dizziness.

Wait until you have fully recovered and no longer feel mentally confused or dizzy before resuming driving, using tools or machinery, or engaging in any activity where lack of concentration could put yourself and others at serious risk.

3. How to use Lecigimon

Use Lecigimon exactly as directed by your doctor, nurse, or pharmacist.
If you have any doubts, consult your doctor, nurse, or pharmacist.

How Lecigimon is administered
Lecigimon is a gel that, delivered via a portable pump (Crono LECIG) and a tube (catheter), reaches directly the upper part of the small intestine. The gel is contained in a cartridge connected to the pump. The pump is connected to a catheter that has been surgically placed into the intestine through the abdominal wall.
The pump delivers a small, continuous dose throughout the day. This helps maintain stable blood levels of the medicine. As a result, certain side effects—such as those affecting movement—are generally less severe than those observed with orally administered medications.

Before the catheter is inserted into the small intestine, your doctor may decide to test whether treatment with Lecigimon is effective for you. In such cases, the gel is administered through a tube passed through the nose, throat, and stomach into the small intestine.

A user manual with instructions for operating the pump is provided with the portable pump.

Dosage
Your doctor will individually adjust the dosage based on the medication you previously took.
Dosage adjustments may be necessary during the first few weeks of treatment.

A higher initial dose (called a "bolus dose") is usually administered in the morning at the start of treatment to rapidly achieve adequate blood levels of the medicine.
Afterward, a continuous maintenance dose is administered during waking hours (typically about 16 hours). If necessary, your doctor may decide to administer Lecigimon continuously for 24 hours per day.
Additional doses may be given as needed. Some individuals may also need to increase or decrease their continuous maintenance dose during the day. When and how to take supplemental doses or adjust the dosage during the day will be determined by your doctor after consultation with you.

The total daily dose, including the morning bolus dose, maintenance dose, and any supplemental doses, must not exceed 100 ml (equivalent to 2000 mg of levodopa, 500 mg of carbidopa, and 2000 mg of entacapone).

If the user has dementia, the doctor may decide that the pump should only be handled by a healthcare professional or a caregiver. The pump can be locked to prevent accidental overdose.

Opened cartridge
The medication cartridge is for single use only and must not be used for longer than 24 hours, even if some gel remains. The dosing pump with the installed cartridge may be worn close to the body for up to 16 hours. During nighttime treatment, the pump should not be worn close to the body but may, for example, be placed on a bedside table. If treatment is interrupted during the night, you may continue using the opened cartridge the following day, but only if less than 24 hours have passed since first opening. Do not remove the cartridge from the pump until it is fully used (i.e., before 24 hours have elapsed from opening or when it is empty, whichever occurs first).

Toward the end of the storage period, the gel may become slightly yellowish/reddish. This does not affect the effectiveness of the treatment.

If you use more Lecigimon than you should
Contact your doctor immediately if you notice any signs of overdose.
Signs of overdose may include:

• Eyelid spasms or cramps making it difficult to open the eyes.
• Involuntary and sustained muscle contractions leading to repetitive twisting movements or abnormal body postures (dystonia).
• Involuntary movements (dyskinesia).
• Unusually fast, slow, or irregular heartbeat.
• Confusion or anxiety/restlessness.
• Changes in the color of the skin, tongue, eyes, or urine.

If you forget to use Lecigimon
Restart the pump with the prescribed dose as soon as possible. Do not increase the dose to make up for the missed dose.

If you stop or reduce the dose of Lecigimon
Do not stop taking Lecigimon or reduce the dose unless instructed by your doctor.
This is because sudden discontinuation or rapid reduction of Lecigimon may lead to serious conditions known as neuroleptic malignant syndrome and rhabdomyolysis. These conditions are more likely to occur if you are also taking a medication for a serious psychiatric condition. For more information about these conditions, see section 4 “Possible side effects”.

If treatment is suspended, you will be given an alternative treatment. If treatment with Lecigimon is permanently discontinued, the catheter will be removed and the wound allowed to heal.

If you have any questions about the use of this medicine, consult your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. To reduce the risk of side effects, it is important that the dose of the medicine is individually adjusted and that the pump is properly set.

Serious side effects of Lecigimon
If you experience any of the following symptoms while being treated with Lecigimon, contact a doctor immediately – urgent medical treatment may be required:

• Itching, hives, swelling of the face, lips, tongue or throat, which may lead to difficulty breathing or swallowing. Drop in blood pressure. These could be signs of a severe allergic reaction (rare adverse effect).
• A combination of muscle rigidity, cramps, tremors, sweating, fever, rapid pulse, acting out, confusion, loss of consciousness. These may be symptoms of a serious condition known as neuroleptic malignant syndrome (frequency cannot be estimated from available data).
• Unexplained muscle pain, muscle cramps or muscle weakness, which may be signs of rhabdomyolysis, a rare and serious muscle disorder associated with the breakdown of muscle cells that could severely affect the kidneys (frequency not known – cannot be determined from available data). Rhabdomyolysis may occur secondary to neuroleptic malignant syndrome. For further information on neuroleptic malignant syndrome and rhabdomyolysis, see section 3 "If you stop or reduce the dose of Lecigimon".
• Stomach ache, nausea or vomiting. These may be due to serious problems related to the tube or surgery, e.g. blockage, injury or damage to the intestine (common adverse effect).
• Infection with symptoms such as fever with severely compromised general condition or fever with signs of local infection, such as sore throat/mouth or difficulty urinating. This may indicate impairment of white blood cells, a condition known as agranulocytosis (frequency not known – cannot be determined from available data). Your doctor will take a blood sample to check for this.
• Suicidal thoughts or suicide attempts (uncommon adverse effect).

Other side effects of Lecigimon
Very common (may affect more than 1 in 10 people):

• Weight loss
• Worry, anxiety, depression, insomnia.
• Involuntary movements (dyskinesia)
• Worsening of Parkinson’s disease symptoms.
• Dizziness when standing up or changing position (orthostatic hypotension) – this is due to low blood pressure.
• Nausea, constipation, diarrhoea.
• Pain in muscles, tissues and bones.
• Abnormal urine colour (chromaturia).
• Risk of falls.

Common (may affect up to 1 in 10 people):

• Anaemia.
• High levels of amino acids (e.g. homocysteine) in the blood, deficiency of vitamin B6 and B12.
• Loss of appetite, weight gain.
• Nightmares, acting out, restlessness, confusion, hallucinations, psychotic disorders.
• Sudden sleep attacks, drowsiness, sleep disorders.
• Dizziness, fainting, headache.
• Reduced sense of touch, tingling or numbness of the skin.
• Nerve disorders, with discomfort, pain and tingling, particularly in the feet (polyneuropathy).
• Involuntary and sustained muscle contractions leading to repetitive twisting movements or abnormal body postures (dystonia), excessive movements (hyperkinesia), tremors (tremor).
• Fluctuations in response to Parkinson’s symptoms (On/Off episodes).
• Blurred vision.
• Irregular heartbeat, cardiovascular diseases other than heart attack (e.g. angina).
• Low or high blood pressure.
• Breathing difficulties, pneumonia due to foreign material in the lungs.
• Sore throat or mouth.
• Abdominal distension, abdominal pain, abdominal discomfort, sensitive stomach with pain, heartburn, bloating, vomiting.
• Dry mouth, altered sense of taste.
• Difficulty swallowing, sore throat.
• Contact dermatitis, itching, rash.
• Severe sweating.
• Pain, joint pain, neck pain, muscle spasms.
• Urinary incontinence, difficulty urinating, urinary tract infection.
• Feeling of weakness, fatigue, chest pain.
• Gait disturbances.
• Swelling of legs or feet.

Impulse control disorders – behavioural changes. This is a common adverse effect (may affect up to 1 in 10 people). Inability to resist the impulse to perform an action that may be harmful, including:

• A strong urge to gamble excessively, despite serious personal or family consequences.
• Altered or increased sexual thoughts and behaviour causing significant concern to you or others. This may include increased sexual desire.
• Uncontrollable shopping or spending.
• Uncontrolled eating (eating large amounts of food in a short period of time) or compulsive eating (eating more food than normal and more than needed to satisfy appetite).

Inform your doctor if you, your family or caregiver notice any of these behaviours. Your doctor will decide with you how to manage or reduce these symptoms.

Uncommon (may affect up to 1 in 100 people):

• Low number of white blood cells or platelets in the blood, which may cause bleeding.
• Suicide.
• Confusion, elevated mood (euphoria), fear, nightmares.
• Difficulty coordinating muscle movements, seizures.
• Spasms or cramps of the eyelids making it difficult to open the eyes, double vision, optic nerve damage, closed-angle glaucoma (acute high pressure in the eye).
• Palpitations, heart attack.
• Inflammation of veins.
• Voice changes.
• Inflammation of the large intestine, bleeding in the gastrointestinal tract.
• Abnormally high production of saliva.
• Abnormal liver function tests.
• Skin redness, hives.
• Hair loss, changes in nail, skin, hair or sweat colour.
• Malaise.

Rare (may affect up to 1 in 1,000 people):

• Abnormal thoughts.
• Abnormal breathing pattern.
• Teeth grinding, tongue pain, change in saliva colour.
• Hiccups.
• Skin cancer (malignant melanoma) (see section 2 “Do not use Lecigimon”).
• Persistent and painful erection.

Other reported adverse effects (frequency cannot be estimated from available data):

• Inflammation of the liver (hepatitis).
• Abnormal laboratory results from blood and urine tests.
• Memory impairment, dementia.
• Desire for high doses of Lecigimon exceeding those required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe involuntary abnormal movements (dyskinesias), mood changes or other adverse effects after taking high doses of Lecigimon.

Side effects due to the pump, tube or surgery:
Very common (may affect more than 1 in 10 people):

• Abdominal pain.
• Wound infection after surgery.
• Thickening of the scar at the incision site.
• Problems with tube insertion, such as pain or swelling in the mouth or throat, difficulty swallowing, discomfort, pain or swelling in the stomach, injury to throat, mouth or stomach, internal bleeding, vomiting, bloated stomach, anxiety.
• Problems at the incision site: redness, open sore, discharge from the stoma, pain or irritation.

Common (may affect up to 1 in 10 people):

• Abdominal discomfort, upper abdominal pain.
• Infection at the incision site or in the intestine, post-procedure infection after the tube is placed in the intestine.
• Inflammation of the peritoneum (peritonitis).
• Displacement of the tube in the intestine, e.g. into the stomach, or tube occlusion – this may cause a reduced response to treatment.
• Problems in the gastrointestinal tract due to the stoma (where the tube enters the abdomen), incision pain, cessation of intestinal movements after surgery, and post-procedure discomfort or bleeding.

Uncommon (may affect up to 1 in 100 people):

• Inflammation of the large intestine or pancreas.
• Inflammation of the pancreas (pancreatitis).
• The tube penetrates the wall of the large intestine.
• Intestinal obstruction, bleeding or ulcer in the small intestine.
• Slipping of one part of the intestine into an adjacent part (intussusception).
• Undigested food becoming lodged around the tube causing occlusion.
• Abscess following insertion of the tube into the intestine.

Other reported adverse effects (frequency cannot be estimated from available data):

• Reduced blood flow in the small intestine.
• The tube penetrates the stomach wall or small intestine.

Side effects of orally administered levodopa and carbidopa
The following adverse effects have been reported when levodopa and carbidopa (the same active substances as in Lecigimon) were taken by mouth. These adverse effects could also occur with Lecigimon.

Rare (may affect up to 1 in 1,000 people):

• Anaemia due to increased breakdown of red blood cells.
• Inability to fully open the mouth.
• Symptoms affecting one side of the face, including drooping eyelids (Horner’s syndrome).
• Pupil dilation, convulsive eye movements fixed in one position, usually upwards.
• Inflammation of small blood vessels causing, among other things, raised bruises (Schönlein-Henoch purpura).

Very rare (may affect up to 1 in 10,000 people):

• Blood count abnormalities.

Reporting of adverse effects
If you experience any adverse effect, including those not listed in this leaflet, talk to your doctor, pharmacist or nurse. You can also report adverse effects directly via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. How to store Lecigimon

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the label and packaging
following the term EXP. The expiry date refers to the last day of that month.
Unopened cartridge: Store in a refrigerator (2°C — 8°C). Do not freeze.
Keep in the original packaging to protect the product from light.
Opened cartridge: Use immediately. The cartridge may be used up to 24 hours after
removal from the refrigerator. The dosing pump with the installed cartridge may be worn
close to the body for a maximum of 16 hours. During overnight treatment, the pump must not be
worn close to the body, but may, for example, be kept on a bedside table. Dispose of any unused
residual product within 24 hours.
Cartridges are for single use only. Do not reuse an opened cartridge.
Do not dispose of any medicine via wastewater or household waste. Ask your pharmacist how to
dispose of medicines no longer required. This will help protect the environment.

6. Package contents and other information

What Lecigimon contains:

• The active substances are levodopa, carbidopa monohydrate and entacapone. 1 ml contains 20 mg of levodopa, 5 mg of carbidopa monohydrate and 20 mg of entacapone.
• The other components are sodium carmellose, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment) and water.

Description of the appearance of Lecigimon and contents of the pack
Lecigimon intestinal gel is a viscous, opaque gel, yellow or yellowish-red in colour.
A plastic cartridge contains 47 ml of intestinal gel.
Each pack contains 7 cartridges.

Marketing Authorization Holder
LobSor Pharmaceuticals AB
Kålsängsgränd 10 D
SE-753 19 Uppsala, Sweden
[email protected]

Manufacturer
Bioglan AB
Borrgatan 31
211 24 Malmö
Sweden

This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Austria Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml Gel zur intestinalen Anwendung
Belgium Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml, gel intestinal
Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml gel voor intestinaal gebruik
Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml Gel zur intestinalen Anwendung
Bulgaria Лесигон 20 mg/ml + 5 mg/ml + 20 mg/ml гел за прилагане в червата
Croatia Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinalni gel
Denmark Lecigon enteralgel
Finland Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml geeli suoleen
France Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml, gel intestinal
Germany Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml Gel zur intestinalen Anwendung
Ireland Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinal gel
Italy Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml gel intestinale
Norway Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinalgel
Netherlands Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml gel voor intestinaal gebruik
Poland Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml żel dojelitowy
Portugal Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml gel intestinal
Czech Republic Lecigimon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinální gel
Slovakia Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinálny gél
Romania Lecigon 20 mg/5 mg/20 mg/ml gel intestinal
Slovenia Lecigon 20 mg/5 mg/20 mg v 1 ml intestinalni gel
Spain Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml gel intestinal
Sweden Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinal gel
Hungary Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intesztinális gél